HaemaLogiX welcomes Tertia Dex to the team
17 January 2022
HaemaLogiX warmly welcomes Tertia Dex to the HaemaLogiX team as our Chief Manufacturing & Development Officer. Tertia is an expert in Chemistry, Manufacturing, and Controls (CMC) and program management.
Her experience includes Director of Program Management & Business Management at Patheon Biologics where she delivered clinical and commercial programs across multiple therapeutic areas. Prior to that, she held numerous leadership and technical roles in process & analytical development, technology transfer, scale-up and cGMP manufacture, bioprocess management, validation, and commercialisation within both product development companies and contract development and manufacturing organisations including Lonza, UK.
Tertia holds a Bachelor of Biotechnology with First Class Honours at Griffith University, Qld, Australia.